Brief: Adocia Announces Positive Clinical Results For BioChaperone Lispro

Adocia SA

25/01/2021 17:18

Jan 25 (Reuters) - ADOCIA SA  ADOC.PA :
    * ADOCIA ANNOUNCES POSITIVE CLINICAL RESULTS CONFIRMING THE
ULTRA-RAPID PROFILE OF A BIOCHAPERONE® LISPRO FORMULATION
CONTAINING INSULIN FROM PARTNER TONGHUA DONGBAO
    * STUDY CONFIRMS PERFORMANCE OF INSULIN LISPRO DRUG
SUBSTANCE
SUPPLIED BY OUR STRATEGIC PARTNER, TONGHUA DONGBAO
    * RESULTS FROM THIS STUDY COMPLETE DOSSIER FOR BIOCHAPERONE
LISPRO, EMPLOYING INSULIN LISPRO FROM TONGHUA DONGBAO, REQUIRED
FOR INITIATION OF PHASE 3 STUDIES IN CHINA, EUROPE, AND US
    * THIS IS A VERY IMPORTANT STEP FOR ADOCIA AS WE NOW FEATURE
A
PRODUCT READY FOR PHASE 3 STUDIES WORLDWIDE - DEPUTY CEO
    * "THESE RESULTS ARE QUITE VALUABLE FOR BOTH COMPANIES, AS
THEY
MAY SERVE TO ADVANCE LAUNCH OF PHASE 3 STUDIES OF BC LISPRO IN
2021 IN CHINA", COMMENTS DR CHUNSHENG LENG, TONGHUA DONGBAO CEO
    * OUR PRIORITY REMAINS TO FIND A PARTNER TO LEAD PHASE 3
PROGRAM
FOR EUROPE AND UNITED STATES - DEPUTY CEO

Source text for Eikon:  ID:nBw4MKhVna 
Further company coverage:  ADOC.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))